• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, February 7, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

TB vaccination could be overall cost-effective in 73 of 105 LMICs (70%) and produce economic benefits of US $474 billion by 2050, per modelling study by researchers at Harvard, LSHTM, the WHO and IAVI

Bioengineer by Bioengineer
January 24, 2023
in Health
Reading Time: 2 mins read
0
TB vaccination could be overall cost-effective in 73 of 105 LMICs (70%) and produce economic benefits of US $474 billion by 2050, per modelling study by researchers at Harvard, LSHTM, the WHO and IAVI
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In your coverage, please use this URL to provide access to the freely available paper in PLOS Medicine: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004155

TB vaccination could be overall cost-effective in 73 of 105 LMICs (70%) and produce economic benefits of US $474 billion by 2050, per modelling study by researchers at Harvard, LSHTM, the WHO and IAVI

Credit: Portnoy A, et al., 2023, PLOS Medicine, CC-BY 4.0 (https://creativecommons.org/licenses/by/4.0/)

In your coverage, please use this URL to provide access to the freely available paper in PLOS Medicine: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004155

Article Title: The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study

Author Countries: United States, United Kingdom, Netherlands, Switzerland, China

Funding: see manuscript



Journal

PLoS Medicine

DOI

10.1371/journal.pmed.1004155

Method of Research

Computational simulation/modeling

Subject of Research

Not applicable

COI Statement

Competing interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Members of the funder (NG, MZ, SYS, RH, IGB, NN) participated as authors on the study and critically reviewed the analysis, reviewed and revised the manuscript, and approved the final manuscript as submitted. All other authors have declared that no competing interests exist.

Share12Tweet8Share2ShareShareShare2

Related Posts

Phage-Antibiotic Combo Beats Resistant Peritoneal Infection

February 7, 2026

Boosting Remote Healthcare: Stepped-Wedge Trial Insights

February 7, 2026

Barriers and Boosters of Seniors’ Physical Activity in Karachi

February 7, 2026

Evaluating Pediatric Emergency Care Quality in Ethiopia

February 7, 2026

POPULAR NEWS

  • Robotic Ureteral Reconstruction: A Novel Approach

    Robotic Ureteral Reconstruction: A Novel Approach

    82 shares
    Share 33 Tweet 21
  • Digital Privacy: Health Data Control in Incarceration

    63 shares
    Share 25 Tweet 16
  • Study Reveals Lipid Accumulation in ME/CFS Cells

    57 shares
    Share 23 Tweet 14
  • Breakthrough in RNA Research Accelerates Medical Innovations Timeline

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Phage-Antibiotic Combo Beats Resistant Peritoneal Infection

Boosting Remote Healthcare: Stepped-Wedge Trial Insights

Barriers and Boosters of Seniors’ Physical Activity in Karachi

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 73 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.